Atorvastatin Calcium Hydrate/Hyzetimibe

阿托伐他汀钙/海泽麦布

Report date: 2026/03/13 20:02:36

Base Information

Drug NameAtorvastatin Calcium Hydrate/Hyzetimibe
Drug Alias Name阿托伐他汀钙海泽麦布Atorvastatin calcium+HS-25海泽麦布阿托伐他汀钙HS-25 + atorvastatin calcium海泽麦布+阿托伐他汀钙 +[11] 
ClassificationSmall molecules
Mechanisms of ActionCholesterol absorption inhibitorsNiemann-Pick C1-like protein 1 inhibitors
TargetsNiemann-Pick C1-like protein 1
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaHyperlipidemias +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes HybutimibeAtorvastatin Calcium Hydrate
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang Hisun Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHanhui Pharmaceuticals Company Ltd
Inactive CompaniesZhejiang Hisun Pharmaceutical Co Ltd
Active IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaHyperlipidemias +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeC10BA
Related LinksN/A